KERYX BIOPHARMACEUTICALS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | |
|---|---|---|---|---|---|---|
| Revenue | $11.8M | $6.8M | $1.2M | $10.8M | $7.0M | $0 |
| Operating income | −$23.1M | −$23.4M | −$27.8M | −$13.7M | −$47.1M | −$27.1M |
| Net income | −$23.0M | −$41.0M | −$27.7M | −$13.5M | −$46.7M | −$22.7M |
| Total assets | $158.9M | $141.4M | $258.7M | $103.6M | $60.8M | $18.6M |
| Total liabilities | $173.0M | $149.7M | $171.8M | $30.1M | $15.4M | $8.1M |
| Equity | −$14.1M | −$8.3M | $86.9M | $73.5M | $45.4M | $10.5M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 107.7M | 105.9M | 103.6M | 90.9M | 81.7M | 71.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2017- Operating margin
- −195.5%
- Net margin
- −194.7%
- Return on equity
- 163.3%
- Return on assets
- −14.5%
- Return on capital (ROCE)
- −20.4%
- Liabilities / assets
- 108.9%
- Debt / equity
- —
- Book value / share
- $-0.13
- Revenue growth (YoY)
- 73.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2017- Altman Z″ (distress)
- -17.58distress
- Accruals / assets
- 44.4%high accruals
- Beneish M-Score
- 1.05elevated
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 6 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
- Beneish M-Score elevated — earnings-manipulation screen flag
- Strong return on equity (>15%)
- Revenue is growing year-over-year
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Rogers Michael WDirector | Dec 12, 2018 | D | 30,000 | — |
| Enyedy Mark JDirector | Dec 12, 2018 | D | 10,000 | — |
| Holmes Scott AOfficer — Chief Financial Officer | Dec 12, 2018 | D | 162,956 | — |
| Morrison Jodie PopeOfficer — Interim CEO | Dec 12, 2018 | D | 120,000 | — |
| Regan Daniel PaulDirector | Dec 12, 2018 | D | 60,000 | — |
| Heffernan Michael ThomasDirector | Dec 12, 2018 | D | 20,000 | — |
| Gilman Steven CDirector | Dec 12, 2018 | D | 27,333 | — |
| Neylan John F.Officer — Chief Medical Officer | Dec 12, 2018 | D | 148,279 | — |
| Cameron Kevin JDirector | Dec 12, 2018 | D | 186,666 | — |
| Carberry Christine A.Officer — Chief Operating Officer | Dec 11, 2018 | Sell | 10,469 | $3.22 |
| Baupost Group Llc/MaDirector | Dec 11, 2018 | Grant | 35.6M | $4.63 |
| Neylan John F.Officer — Chief Medical Officer | Nov 15, 2018 | Sell | 1,156 | $2.77 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Shareholder voteDec 13, 2018
- Results of operationsNov 8, 2018
- Entered a material agreement · Other material eventOct 25, 2018
- Entered a material agreement · Other material eventOct 1, 2018
- Results of operationsAug 8, 2018
- Entered a material agreement · New financial obligationJul 20, 2018
- Shareholder voteJul 3, 2018
- Entered a material agreement · Unregistered equity sale · Amended charter or bylaws · Other material eventJun 28, 2018
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- CT ORDERJun 26, 2020
- 15-12GDec 26, 2018
- EFFECTDec 21, 2018
- EFFECTDec 21, 2018
- EFFECTDec 21, 2018
- EFFECTDec 21, 2018
- EFFECTDec 21, 2018
- EFFECTDec 21, 2018
- EFFECTDec 21, 2018
- EFFECTDec 21, 2018
- EFFECTDec 21, 2018
- EFFECTDec 21, 2018
- 4FORM 4 SUBMISSIONDec 13, 2018
- 4FORM 4 SUBMISSIONDec 13, 2018
- 4FORM 4 SUBMISSIONDec 13, 2018
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.